HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Effect of combining ACE inhibition with aldosterone blockade on proteinuria and renal damage in experimental nephrosis.

Abstract
Aldosterone has pro-fibrotic properties and is a potential target for additional intervention in patients with chronic renal disease showing resistance to therapy during treatment with angiotensin-converting enzyme inhibitors (ACEi). Combining ACEi and aldosterone receptor blockade (aldoRB) in proteinuric renal disease reduces proteinuria, but effects on proteinuria-induced renal damage are unknown. We studied the effect of ACEi/aldoRB in adriamycin nephrosis (AN). Six weeks after injection of adriamycin in Wistar rats, randomized treatment with vehicle (VEH, n=8), aldoRB (n=12), ACEi (n=10), or a combination of ACEi/aldoRB (n=14) was given for 12 weeks. Healthy rats served as controls (n=6). Renal damage was quantified by markers of tubular injury (osteopontin (OPN) and kidney injury molecule-1 (Kim-1)), pre-fibrotic lesions (alpha-smooth muscle actin (SMA)), interstitial fibrosis (IF), and focal glomerulosclerosis (FGS). In AN animals, proteinuria was increased compared with controls. ACEi and ACEi/aldoRB significantly reduced proteinuria compared with VEH, whereas aldoRB monotherapy was without effect. Blood pressure was reduced in ACEi and ACEi/aldoRB compared with VEH and aldoRB. OPN and Kim-1 were increased in AN animals, but significantly reduced by ACEi/aldoRB. Treatment with ACEi and ACEi/aldoRB prevented an increase of SMA, IF, and FGS. In conclusion, ACEi/aldoRB effectively reduced proteinuria and markers of tubular injury and prevented renal damage in this rat model of chronic proteinuria-induced renal damage.
AuthorsA B Kramer, E F van der Meulen, I Hamming, H van Goor, G Navis
JournalKidney international (Kidney Int) Vol. 71 Issue 5 Pg. 417-24 (Mar 2007) ISSN: 0085-2538 [Print] United States
PMID17213874 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Actins
  • Angiotensin-Converting Enzyme Inhibitors
  • Biomarkers
  • Cell Adhesion Molecules
  • Collagen Type IV
  • Havcr1protein, rat
  • Membrane Proteins
  • Mineralocorticoid Receptor Antagonists
  • smooth muscle actin, rat
  • Osteopontin
  • Aldosterone
  • Peptidyl-Dipeptidase A
Topics
  • Actins (analysis)
  • Aldosterone (metabolism)
  • Angiotensin-Converting Enzyme Inhibitors (therapeutic use)
  • Animals
  • Biomarkers (analysis)
  • Blood Pressure (drug effects)
  • Cell Adhesion Molecules (analysis)
  • Collagen Type IV (analysis)
  • Disease Models, Animal
  • Drug Therapy, Combination
  • Glomerulosclerosis, Focal Segmental (prevention & control)
  • Kidney (chemistry, pathology)
  • Membrane Proteins (analysis)
  • Mineralocorticoid Receptor Antagonists (therapeutic use)
  • Nephrosis (drug therapy, etiology, pathology)
  • Osteopontin (analysis)
  • Peptidyl-Dipeptidase A (metabolism)
  • Proteinuria (complications, drug therapy)
  • Rats
  • Rats, Wistar

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: